

Andrew M Jones

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8728002/publications.pdf>

Version: 2024-02-01

108
papers

3,429
citations

172457

29
h-index

149698

56
g-index

110
all docs

110
docs citations

110
times ranked

4952
citing authors

#	ARTICLE	IF	CITATIONS
1	Daily sitting time and its association with non-communicable diseases and multimorbidity in Catalonia. <i>European Journal of Public Health</i> , 2022, 32, 105-111.	0.3	0
2	Review article: epidemiology, pathogenesis and management of liver disease in adults with cystic fibrosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 389-400.	3.7	10
3	Managing Pulmonary Infection in Adults With Cystic Fibrosis. <i>Chest</i> , 2022, 162, 66-75.	0.8	9
4	Isolation of <i>Exophiala dermatitidis</i> is not associated with worse clinical outcomes during acute pulmonary exacerbations in cystic fibrosis. <i>Journal of Medical Microbiology</i> , 2022, 71, .	1.8	2
5	Tobacco Smoking Rates in a National Cohort of People with Substance Use Disorder Receiving Treatment. <i>European Addiction Research</i> , 2021, 27, 151-155.	2.4	4
6	Estimates of the Incidence of Crack Cocaine Use in Those Likely to Attend Treatment in the English Population, 2005â€“2018. <i>European Addiction Research</i> , 2021, 27, 83-86.	2.4	1
7	Longitudinal effects of ivacaftor and medicine possession ratio in people with the <i>Gly551Asp</i> mutation: a 5-year study. <i>Thorax</i> , 2021, 76, 874-879.	5.6	20
8	Did paying drugs misuse treatment providers for outcomes lead to unintended consequences for hospital admissions? Difference-in-differences analysis of a pay-for-performance scheme in England. <i>Addiction</i> , 2021, 116, 3082-3093.	3.3	4
9	Diagnosis and management of non-cystic fibrosis bronchiectasis. <i>Clinical Medicine</i> , 2021, 21, e571-e577.	1.9	8
10	Meteorological Factors Influence the Presence of Fungi in the Air; A 14-Month Surveillance Study at an Adult Cystic Fibrosis Center. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 759944.	3.9	6
11	Structured surveillance of <i>Achromobacter</i> , <i>Pandoraea</i> and <i>Ralstonia</i> species from patients in England with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2020, 19, 388-393.	0.7	10
12	Influenza B outbreak at an adult cystic fibrosis centre - Clinical impact and factors influencing spread. <i>Journal of Cystic Fibrosis</i> , 2020, 19, 808-814.	0.7	6
13	Royal Society of Medicine Cystic Fibrosis Symposium 2019. <i>Paediatric Respiratory Reviews</i> , 2020, 35, 88-89.	1.8	0
14	Lung clearance index in healthy volunteers, measured using a novel portable system with a closed circuit wash-in. <i>PLoS ONE</i> , 2020, 15, e0229300.	2.5	4
15	Sputum trypsin-like protease activity relates to clinical outcome in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2020, 19, 647-653.	0.7	6
16	Antibiotic treatment for <i>Burkholderia cepacia</i> complex in people with cystic fibrosis experiencing a pulmonary exacerbation. <i>The Cochrane Library</i> , 2020, 4, CD009529.	2.8	20
17	Title is missing!. , 2020, 15, e0229300.		0
18	Title is missing!. , 2020, 15, e0229300.		0

#	ARTICLE	IF	CITATIONS
19	Title is missing!. , 2020, 15, e0229300.		0
20	Title is missing!. , 2020, 15, e0229300.		0
21	Title is missing!., 2020, 15, e0229300.		0
22	Title is missing!. , 2020, 15, e0229300.		0
23	A general protein O-glycosylation machinery conserved in Burkholderia species improves bacterial fitness and elicits glycan immunogenicity in humans. <i>Journal of Biological Chemistry</i> , 2019, 294, 13248-13268.	3.4	27
24	Assessing arthritis in the context of cystic fibrosis. <i>Pediatric Pulmonology</i> , 2019, 54, 770-777.	2.0	10
25	The diagnosis of Cystic Fibrosis: Controversies and consensus on common grounds. <i>Paediatric Respiratory Reviews</i> , 2019, 31, 1-2.	1.8	0
26	After the Celebrations: Lessons from the New Era of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy. <i>Annals of the American Thoracic Society</i> , 2019, 16, 189-190.	3.2	0
27	Which pathogens should we worry about?. <i>Paediatric Respiratory Reviews</i> , 2019, 31, 15-17.	1.8	13
28	Investigation of a <i>Pandora</i> cluster common to adult and paediatric cystic fibrosis patients attending two hospitals in the same city. <i>Journal of Medical Microbiology</i> , 2019, 68, 1081-1095.	1.8	3
29	Improvement in <i>Exophiala dermatitidis</i> airway persistence and respiratory decline in response to interferon-gamma therapy in a patient with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2018, 17, e32-e34.	0.7	7
30	CFTR modulator therapy in patients with cystic fibrosis and an organ transplant. <i>Paediatric Respiratory Reviews</i> , 2018, 27, 6-8.	1.8	13
31	Effectiveness of inpatient withdrawal and residential rehabilitation interventions for alcohol use disorder: A national observational, cohort study in England. <i>Journal of Substance Abuse Treatment</i> , 2018, 88, 1-8.	2.8	12
32	Effectiveness of community psychosocial and pharmacological treatments for alcohol use disorder: A national observational cohort study in England. <i>Drug and Alcohol Dependence</i> , 2018, 186, 60-67.	3.2	10
33	Emerging Gram-negative bacteria. <i>Current Opinion in Pulmonary Medicine</i> , 2018, 24, 592-598.	2.6	22
34	Royal society of medicine cystic fibrosis symposium 2017. <i>Paediatric Respiratory Reviews</i> , 2018, 27, 1.	1.8	0
35	Ivacaftor for cystic fibrosis. <i>BMJ: British Medical Journal</i> , 2018, 361, k1783.	2.3	3
36	Development of a resource allocation formula for substance misuse treatment services. <i>Journal of Public Health</i> , 2018, 40, e396-e404.	1.8	2

#	ARTICLE	IF	CITATIONS
37	The diagnosis and management of respiratory viral infections in cystic fibrosis. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 221-227.	2.5	23
38	A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2017, 16, 695-701.	0.7	4
39	High level of β -(1,3)-d-glucan antigenaemia in cystic fibrosis in the absence of invasive fungal disease. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 88, 316-321.	1.8	9
40	Noninvasive assessment of subclinical atherosclerosis in persons with symptoms of depression. <i>Atherosclerosis</i> , 2017, 264, 92-99.	0.8	17
41	Levels of Motivation and Readiness for Treatment Aligned With Criminal Justice Referral and Coercion Among Substance Users in England. <i>Journal of Studies on Alcohol and Drugs</i> , 2017, 78, 884-888.	1.0	3
42	Antibiotic treatment for <i>Burkholderia cepacia</i> complex in people with cystic fibrosis experiencing a pulmonary exacerbation. <i>The Cochrane Library</i> , 2016, , CD009529.	2.8	39
43	Increased prevalence of <i>Pneumocystis jirovecii</i> colonisation in acute pulmonary exacerbations of cystic fibrosis. <i>Journal of Infection</i> , 2016, 73, 1-7.	3.3	14
44	Impact of treatment for opioid dependence on fatal drug-related poisoning: a national cohort study in England. <i>Addiction</i> , 2016, 111, 298-308.	3.3	124
45	Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. <i>Science</i> , 2016, 354, 751-757.	12.6	462
46	Pneumothorax in cystic fibrosis: beyond the guidelines. <i>Paediatric Respiratory Reviews</i> , 2016, 20, 30-33.	1.8	10
47	Diabetic retinopathy in patients who do not meet the diagnostic criteria for cystic fibrosis related diabetes. <i>Practical Diabetes</i> , 2015, 32, 333-335a.	0.3	4
48	Exhaled breath hydrogen cyanide as a marker of early <i>Pseudomonas aeruginosa</i> infection in children with cystic fibrosis. <i>ERJ Open Research</i> , 2015, 1, 00044-2015.	2.6	40
49	The Microbiome and Emerging Pathogens in Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015, 36, 225-235.	2.1	41
50	New and Emerging Treatments for Cystic Fibrosis. <i>Drugs</i> , 2015, 75, 1165-1175.	10.9	14
51	Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?. <i>Thorax</i> , 2015, 70, 615-616.	5.6	27
52	Rapid Detection of Emerging Pathogens and Loss of Microbial Diversity Associated with Severe Lung Disease in Cystic Fibrosis. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2022-2029.	3.9	82
53	Anabolic agent use in adults with cystic fibrosis. <i>Paediatric Respiratory Reviews</i> , 2015, 16, 28-30.	1.8	3
54	Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015, 36, 167-168.	2.1	2

#	ARTICLE	IF	CITATIONS
55	Airborne dissemination of transmissible bacterial species in cystic fibrosis. <i>Thorax</i> , 2014, 69, 690-691.	5.6	2
56	Incidence and clinical impact of respiratory viruses in adults with cystic fibrosis. <i>Thorax</i> , 2014, 69, 247-253.	5.6	107
57	Reassessment of the importance of mucins in determining sputum properties in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2014, 13, 260-266.	0.7	18
58	Sweat chloride is not a useful marker of clinical response to Ivacaftor. <i>Thorax</i> , 2014, 69, 586-587.	5.6	35
59	What is the importance of classifying <i>Aspergillus</i> disease in cystic fibrosis patients?. <i>Expert Review of Respiratory Medicine</i> , 2014, 8, 389-392.	2.5	21
60	Panton-Valentine Leukocidin-positive <i>Staphylococcus aureus</i> : a potentially significant pathogen in cystic fibrosis. <i>Paediatric Respiratory Reviews</i> , 2014, 15, 22-25.	1.8	2
61	Skin contamination leading to falsely elevated fingerprick tobramycin levels in a patient taking dry powder inhaled tobramycin. <i>Journal of Cystic Fibrosis</i> , 2014, 13, 754.	0.7	0
62	Effects of Ivacaftor in Patients With Cystic Fibrosis Who Carry the G551D Mutation and Have Severe Lung Disease. <i>Chest</i> , 2014, 146, 152-158.	0.8	85
63	Adults with Cystic Fibrosis Should be Treated at a Specialist Centre. <i>Paediatric Respiratory Reviews</i> , 2013, 14, 13-15.	1.8	4
64	IgE-Mediated Immune Responses and Airway Detection of <i>Aspergillus</i> and <i>Candida</i> in Adult Cystic Fibrosis. <i>Chest</i> , 2013, 143, 1351-1357.	0.8	71
65	Liminality and transfer to adult services: A qualitative investigation involving young people with cystic fibrosis. <i>International Journal of Nursing Studies</i> , 2013, 50, 738-746.	5.6	17
66	Novel immunologic classification of aspergillosis in adult cystic fibrosis. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 560-566.e10.	2.9	180
67	Itraconazole and inhaled fluticasone causing hypothalamic-pituitary-adrenal axis suppression in adults with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2013, 12, 399-402.	0.7	33
68	Chronic Rhinovirus Infection in an Adult with Cystic Fibrosis. <i>Journal of Clinical Microbiology</i> , 2013, 51, 3893-3896.	3.9	16
69	Intravenous antibiotics reduce the presence of <i>Aspergillus</i> in adult cystic fibrosis sputum. <i>Thorax</i> , 2013, 68, 652-657.	5.6	62
70	Is Hydrogen Cyanide a Marker of <i>Burkholderia cepacia</i> Complex?. <i>Journal of Clinical Microbiology</i> , 2013, 51, 3849-3851.	3.9	17
71	Hydrogen cyanide concentrations in the breath of adult cystic fibrosis patients with and without <i>Pseudomonas aeruginosa</i> infection. <i>Journal of Breath Research</i> , 2013, 7, 026010.	3.0	63
72	Monitoring of tobramycin levels in patients with cystic fibrosis by finger-prick sampling: Figure 1. <i>European Respiratory Journal</i> , 2012, 39, 1537-1538.	6.7	2

#	ARTICLE	IF	CITATIONS
73	A therapeutic conundrum: recurrent cystic-fibrosis-related haemoptysis complicated by acute pulmonary embolism: Figure 1. <i>Thorax</i> , 2012, 67, 931-932.	5.6	5
74	Quantification of hydrogen cyanide and 2-aminoacetophenone in the headspace of <i>Pseudomonas aeruginosa</i> cultured under biofilm and planktonic conditions. <i>Analytical Methods</i> , 2012, 4, 3661.	2.7	27
75	Long-term non-invasive ventilation in cystic fibrosis – Experience over two decades. <i>Journal of Cystic Fibrosis</i> , 2012, 11, 187-192.	0.7	47
76	An investigation of suitable bag materials for the collection and storage of breath samples containing hydrogen cyanide. <i>Journal of Breath Research</i> , 2012, 6, 036004.	3.0	36
77	Successful treatment of cepacia syndrome with a combination of intravenous cyclosporin, antibiotics and oral corticosteroids. <i>Journal of Cystic Fibrosis</i> , 2012, 11, 458-460.	0.7	26
78	Antibiotic treatment for <i>Burkholderia cepacia</i> complex in people with cystic fibrosis experiencing a pulmonary exacerbation. , 2012, 10, CD009529.		30
79	Rhinovirus infection liberates planktonic bacteria from biofilm and increases chemokine responses in cystic fibrosis airway epithelial cells. <i>Thorax</i> , 2011, 66, 333-339.	5.6	74
80	<i>Burkholderia latens</i> infection in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2011, 10, 291-292.	0.7	6
81	<i>Pseudomonas aeruginosa</i> bacteraemia in an adult with cystic fibrosis and acute appendicitis. <i>Journal of Cystic Fibrosis</i> , 2011, 10, 477-478.	0.7	2
82	Homogenisation of cystic fibrosis sputum by sonication – An essential step for <i>Aspergillus</i> PCR. <i>Journal of Microbiological Methods</i> , 2011, 85, 75-81.	1.6	42
83	Can Early <i>Burkholderia cepacia</i> Complex Infection in Cystic Fibrosis be Eradicated with Antibiotic Therapy?. <i>Frontiers in Cellular and Infection Microbiology</i> , 2011, 1, 18.	3.9	38
84	Anaerobic bacteria in cystic fibrosis: pathogens or harmless commensals?. <i>Thorax</i> , 2011, 66, 558-559.	5.6	21
85	Gout and hyperuricaemia in adults with cystic fibrosis. <i>Journal of the Royal Society of Medicine</i> , 2011, 104, 36-39.	2.0	6
86	Persistent oseltamivir-resistant pandemic influenza A/H1N1 infection in an adult with cystic fibrosis. <i>BMJ Case Reports</i> , 2011, 2011, bcr0220113874-bcr0220113874.	0.5	5
87	Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. <i>Journal of Clinical Investigation</i> , 2011, 121, 3554-3563.	8.2	272
88	Clinical Outcome for Cystic Fibrosis Patients Infected With Transmissible <i>Pseudomonas aeruginosa</i> : An 8-Year Prospective Study. <i>Chest</i> , 2010, 137, 1405-1409.	0.8	42
89	Development of a modern adult cystic fibrosis centre in Manchester. <i>Journal of the Royal Society of Medicine</i> , 2010, 103, 15-19.	2.0	3
90	Emerging Treatments in Cystic Fibrosis. <i>Drugs</i> , 2009, 69, 1903-1910.	10.9	94

#	ARTICLE	IF	CITATIONS
91	Gene expression changes linked to antimicrobial resistance, oxidative stress, iron depletion and retained motility are observed when Burkholderia cenocepacia grows in cystic fibrosis sputum. BMC Infectious Diseases, 2008, 8, 121.	2.9	85
92	Isolation, motivation and balance: living with type 1 or cystic fibrosis-related diabetes. Journal of Clinical Nursing, 2008, 17, 235-243.	3.0	21
93	The changing epidemiology of Burkholderia species infection at an adult cystic fibrosis centre. Journal of Cystic Fibrosis, 2008, 7, 368-372.	0.7	22
94	Temocillin in cystic fibrosis: A retrospective pilot study. Journal of Cystic Fibrosis, 2008, 7, 551-554.	0.7	10
95	Living with cystic fibrosis-related diabetes or type 1 diabetes mellitus: a comparative study exploring health-related quality of life and patients' reported experiences of hypoglycaemia. Chronic Illness, 2008, 4, 278-288.	1.5	14
96	Coagulopathy in two patients with cystic fibrosis treated with ciprofloxacin. Journal of Cystic Fibrosis, 2007, 6, 209-211.	0.7	10
97	Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection. Future Microbiology, 2007, 2, 153-164.	2.0	144
98	Calcium Stone Growth in Urine from Cystic Fibrosis Patients and Healthy Controls. AIP Conference Proceedings, 2007, , .	0.4	0
99	Identification of DNA Markers for a Transmissible Pseudomonas aeruginosa Cystic Fibrosis Strain. American Journal of Respiratory Cell and Molecular Biology, 2005, 33, 56-64.	2.9	32
100	Prospective Surveillance for Pseudomonas aeruginosa Cross-Infection at a Cystic Fibrosis Center. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 257-260.	5.6	52
101	Randomised double blind placebo controlled trial investigating the effect of calcium and vitamin D supplementation on bone mineral density and bone metabolism in adult patients with cystic fibrosis. Journal of Cystic Fibrosis, 2004, 3, 233-236.	0.7	41
102	Recent advances in cross-infection in cystic fibrosis: Burkholderia cepacia complex, Pseudomonas aeruginosa, MRSA and Pandoraea spp. Journal of the Royal Society of Medicine, 2003, 96 Suppl 43, 66-72.	2.0	5
103	Underwater Photography in the Human Airway. Chest, 2002, 122, 384-385.	0.8	0
104	Supplemental Oxygen During Flexible Bronchoscopy. Chest, 2002, 121, 664.	0.8	1
105	Pseudomonas aeruginosa cross-infection in cystic fibrosis. Lancet, The, 2002, 359, 527.	13.7	24
106	Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet, The, 2001, 358, 557-558.	13.7	234
107	Do All Patients Require Supplemental Oxygen During Flexible Bronchoscopy?. Chest, 2001, 119, 1906-1909.	0.8	72
108	Fungal lung disease. , 0, , 186-203.		0